Advancedadvanced biology
The Spliceosome: Cutting and Pasting pre-mRNA
Learning objectives
- Identify the conserved intron signals: 5' splice site, branch point, 3' splice site.
- Trace spliceosome assembly through the E, A, B, and C complexes.
- Describe the two transesterification steps and the lariat intermediate.
- Explain how alternative splicing is regulated by SR proteins and hnRNPs.
- Evaluate the spliceosome's evolutionary relationship to self-splicing introns.
Reading the intron: signals in the pre-mRNA
Splice sites are written in a degenerate code. The 5' splice site almost always begins with GU, the 3' splice site ends with AG, and between them lies the branch point -- typically an adenine embedded in a loosely conserved sequence, preceded by a polypyrimidine tract that helps recruit the machinery. These signals are short and fuzzy, which is both the point and the problem: fuzziness allows regulated alternative splicing, but it also means the spliceosome must distinguish true sites from the countless GU and AG dinucleotides scattered through exons and introns. Auxiliary elements -- exonic and intronic splicing enhancers and silencers -- tip the balance, bound by regulatory proteins that promote or repress nearby sites. The first committed step is U1 snRNP base-pairing to the 5' splice site while splicing factor SF1 and the U2AF heterodimer mark the branch point and polypyrimidine tract, forming the early (E) complex -- a molecular claim staked on this intron.
Assembly: a machine built fresh on every intron
Unlike the ribosome, the spliceosome is not a prebuilt machine -- it assembles anew on each intron and disassembles after catalysis, in a choreography of snRNPs (small nuclear ribonucleoproteins). U2 snRNP displaces SF1 at the branch point, bulging the branch-point adenosine out of its duplex (the A complex). Then the U4/U6.U5 tri-snRNP arrives (B complex): U5 grips the exons, U6 displaces U1 at the 5' splice site, and U4 -- which had been chaperoning U6 -- is ejected. This remodeling, driven by ATP-dependent RNA helicases, creates the activated spliceosome, in which U6 and U2 snRNAs form the catalytic core. The compositional drama is functional: each rearrangement is a proofreading checkpoint, and DEAD-box helicases discard suboptimal substrates, enforcing fidelity. The spliceosome's dynamic assembly -- over a hundred proteins cycling through in order -- makes it among the most complex molecular machines known, rivaling the ribosome in sophistication while being utterly different in architecture.
Two transesterifications and a lariat
Catalysis itself is two sequential transesterification reactions -- no ATP consumed in the chemistry, only in remodeling. First, the 2'-OH of the bulged branch-point adenosine attacks the phosphodiester bond at the 5' splice site, cutting the upstream exon free and joining the intron's 5' end to the branch point -- forming the lariat, an intron looped back on itself through an unusual 2'-5' phosphodiester bond. Second, the freed 3'-OH of the upstream exon attacks the 3' splice site, ligating the two exons and releasing the intron lariat, which is linearized by a debranching enzyme and degraded. The catalytic core is RNA: the U6 snRNA positions metal ions that stabilize the transition states, just as protein enzymes do -- making the spliceosome, like the ribosome, a ribozyme. The chemistry mirrors self-splicing group II introns almost exactly, down to the lariat intermediate, which is the strongest evidence that the spliceosome evolved from mobile group II introns that colonized early eukaryotic genomes.
Alternative splicing: one gene, many proteins
Most human genes contain multiple exons, and the spliceosome does not always join them the same way. Alternative splicing -- exon skipping, alternative 5' or 3' sites, intron retention, mutually exclusive exons -- lets a single gene produce many protein isoforms, and the vast majority of human multi-exon genes are alternatively spliced. Regulation is combinatorial: SR proteins (serine/arginine-rich) generally promote nearby splice sites when bound to enhancers, while hnRNP proteins generally repress; their relative concentrations, set by cell type and signaling, determine the outcome. The examples are textbook classics: sex determination in Drosophila via the Sxl-tra-dsx cascade, where splicing decisions propagate down a regulatory hierarchy, and the DSCAM gene with tens of thousands of potential isoforms guiding neuronal wiring. Alternative splicing massively expands proteomic diversity without expanding gene number -- a major answer to the puzzle of how ~20,000 human genes build a human.
When splicing goes wrong
The spliceosome's reliance on fuzzy signals makes it fragile. Mutations that create cryptic splice sites or destroy real ones cause a large fraction of human genetic disease -- from beta-thalassemia (globin splice-site mutations) to spinal muscular atrophy, where the SMN2 gene's exon 7 is skipped. Remarkably, SMA is now treated with splice-switching antisense oligonucleotides (nusinersen) that mask a silencer and restore exon inclusion -- therapy by reprogramming the spliceosome. Cancer exploits splicing too: mutations in core spliceosomal factors like SF3B1 drive myelodysplasia and other malignancies by systematically altering splice-site choice. The spliceosome's proofreading helicases normally discard bad substrates, but they can be overwhelmed or mutated. Because nearly every human gene is spliced, spliceosome dysfunction is rarely tissue-specific in cause yet often tissue-specific in effect -- a paradox explained by each tissue's distinct alternative-splicing program depending differently on the damaged factor.
The spliceosome's catalytic core is U6/U2 RNA positioning metal ions -- it is a ribozyme like the ribosome. But unlike the ribosome it assembles fresh on every intron, with ATP-driven remodeling as proofreading checkpoints.
Key points
- Intron recognition uses the 5' GU, branch-point adenosine, polypyrimidine tract, and 3' AG, refined by enhancer/silencer elements.
- snRNPs assemble stepwise (E, A, B, activated complexes); ATP-dependent helicases remodel the machine and proofread substrates.
- Two transesterifications -- branch-point attack forming the lariat, then exon ligation -- are catalyzed by U6/U2 RNA: the spliceosome is a ribozyme.
- Alternative splicing, regulated by SR proteins and hnRNPs, lets most human genes produce multiple isoforms.
- Splice-site mutations cause diseases from beta-thalassemia to SMA; splice-switching oligonucleotides are now a therapeutic modality.
- The lariat chemistry and catalytic core mirror group II self-splicing introns, supporting a common evolutionary origin.
Common misconceptions
✓ Truth: It assembles anew on every intron from snRNPs and disassembles after catalysis -- a transient machine, not a standing structure.
✓ Truth: The two transesterifications need no ATP; ATP powers the helicase-driven remodeling and proofreading steps between them.
✓ Truth: Alternative splicing joins exons in different combinations per cell type, making intron removal a major source of protein diversity.
Frequently asked questions
What are the key intron signals?
A 5' GU splice site, a branch-point adenosine, a polypyrimidine tract, and a 3' AG splice site -- recognized by U1, U2, and associated factors, modulated by enhancer/silencer elements.
What is the lariat?
The intron intermediate formed when the branch-point adenosine's 2'-OH attacks the 5' splice site, looping the intron through an unusual 2'-5' phosphodiester bond before exon ligation.
Is the spliceosome a ribozyme?
Yes -- its catalytic core is U6/U2 snRNA positioning catalytic metal ions, with the same transesterification chemistry as self-splicing group II introns.
How is alternative splicing regulated?
Combinatorially: SR proteins bound to enhancers generally promote nearby sites, hnRNPs bound to silencers repress them; their cell-type-specific balance decides each exon's fate.
Can splicing defects be treated?
Yes -- nusinersen, an antisense oligonucleotide for spinal muscular atrophy, masks a splicing silencer to restore SMN2 exon 7 inclusion, reprogramming splice-site choice therapeutically.